CATX: Perspective Therapeutics, Inc.
About
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
Current Value
$6.791 Year Return
Current Value
$6.791 Year Return
Key Details
Market Cap
$458.24M
P/E Ratio
-7.3
1Y Stock Return
162.59%
1Y Revenue Growth
-19.63%
Dividend Yield
0.00%
Price to Book
1.4
Strategies that include CATX
Stock's related to CATX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DYN | 35.28% | $3.02B | +182.40% | 0.00% |
| ACET | 29.20% | $84.87M | -10.43% | 0.00% |
| HTGC | 28.03% | - | - | 8.42% |
| RDDT | 26.77% | $24.08B | +303.41% | 0.00% |
| YMAB | 24.90% | $486.41M | +106.46% | 0.00% |
| ICL | 24.84% | $5.65B | -14.79% | 4.46% |
| UBS | 24.78% | $101.46B | +22.78% | 1.10% |
| MP | 24.70% | $2.94B | +14.70% | 0.00% |
| GENI | 24.55% | $1.97B | +71.29% | 0.00% |
| BNT | 24.54% | $7.31B | +67.22% | 0.00% |
| TKR | 24.47% | $5.15B | +0.82% | 1.84% |
| NKLA | 24.37% | $118.08M | -93.09% | 0.00% |
| CLLS | 24.25% | $141.30M | -30.99% | 0.00% |
| CSWC | 24.01% | $1.10B | +4.09% | 9.96% |
| ABX | 23.49% | $30.98B | +9.45% | 2.27% |
| SON | 23.47% | $4.83B | -10.64% | 4.20% |
| ENTA | 23.44% | $199.60M | -5.52% | 0.00% |
| WFG | 23.31% | $7.42B | +21.08% | 1.35% |
| DHR | 23.20% | $166.73B | +5.96% | 0.46% |
| FLGT | 23.13% | $519.98M | -37.82% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STOK | -0.01% | $614.95M | +197.69% | 0.00% |
| PKE | 0.02% | $291.84M | -1.22% | 3.42% |
| SPH | 0.02% | $1.15B | +6.07% | 7.25% |
| ABEO | 0.02% | $256.04M | +41.25% | 0.00% |
| HUYA | -0.04% | $233.16M | +14.40% | 0.00% |
| HPQ | -0.05% | $35.53B | +32.29% | 2.99% |
| UFI | -0.06% | $102.66M | -11.22% | 0.00% |
| ARQ | -0.06% | $332.89M | +216.80% | 0.00% |
| BROS | -0.06% | $5.67B | +74.77% | 0.00% |
| RLX | 0.07% | $1.69B | -17.76% | 0.00% |
| TLPH | -0.07% | $11.41M | +9.85% | 0.00% |
| VIST | 0.07% | $4.75B | +67.10% | 0.00% |
| CGNT | -0.08% | $501.83M | +59.73% | 0.00% |
| ATEN | -0.08% | $1.21B | +34.32% | 1.46% |
| DT | 0.10% | $15.40B | -1.30% | 0.00% |
| MMC | -0.11% | $108.41B | +10.89% | 1.37% |
| EG | 0.11% | $15.92B | -8.98% | 2.02% |
| AGL | -0.11% | $655.11M | -85.55% | 0.00% |
| TPR | 0.11% | $12.96B | +83.14% | 2.52% |
| RPRX | 0.12% | $11.56B | -3.67% | 3.22% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PULM | -18.99% | $19.83M | +202.98% | 0.00% |
| CBOE | -12.45% | $21.46B | +15.84% | 1.11% |
| OXBR | -12.21% | $19.05M | +178.18% | 0.00% |
| UNFI | -10.13% | $1.31B | +44.06% | 0.00% |
| TEM | -9.87% | $8.50B | 0.00% | 0.00% |
| WTW | -9.72% | $30.98B | +26.60% | 1.13% |
| LAKE | -9.44% | $159.62M | +47.81% | 0.56% |
| OPK | -9.21% | $1.11B | +7.64% | 0.00% |
| HUM | -9.02% | $33.45B | -45.22% | 1.25% |
| BEST | -8.79% | $31.65M | +3.88% | 0.00% |
| CVAC | -8.75% | $560.77M | -54.46% | 0.00% |
| BCAN | -8.47% | $72.87M | -99.75% | 0.00% |
| UEIC | -8.01% | $148.52M | +43.22% | 0.00% |
| XGN | -7.68% | $62.26M | +127.74% | 0.00% |
| OCX | -7.55% | $42.93M | -36.09% | 0.00% |
| TGS | -7.24% | $1.97B | +116.04% | 0.00% |
| CME | -7.19% | $82.76B | +9.21% | 1.98% |
| SOC | -7.02% | $1.93B | +74.70% | 0.00% |
| URGN | -6.94% | $470.95M | -11.92% | 0.00% |
| CHTR | -6.83% | $54.72B | -4.38% | 0.00% |
ETF's related to CATX
News
Finnhub
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor...
Finnhub
[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Eight of nine patients had durable control of disease. Six of nine...
Yahoo
We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Perspective Therapeutics, Inc. (NYSE:CATX) stands against other best multibagger stocks. November has been an eventful month so far for the market as the Fed cut rates by a […]
Yahoo
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking pl
Yahoo
SEATTLE (AP) — Perspective Therapeutics, Inc. CATX) on Tuesday reported a loss of $15.1 million in its third quarter. On a per-share basis, the Seattle-based company said it had a loss of 21 cents.
Yahoo
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in OctoberPresenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor Society Sy
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.